open access
Eprosartan - effect on quality of life in patients with essential hypertension
open access
Abstract
Material and methods The study population consisted of 85 patients with mild to moderate essential hypertension (47 men and 38 women), age 45.1 ± 13.9 yrs. Mean SBP was 154.0 mm Hg and DBP was 99.2 mm Hg. At baseline 16 patients (18.6%) were untreated, and 70 (81.4%) were treated with monotherapy: thiazide-like diuretic (14 pts), beta-blocker (13 pts), ACE inhibitor (20 pts), calcium antagonist (18 pts), alpha-blocker (2 pts), centrally acting drug (3 pts). BP and heart rate were measured at baseline and on each control visit (every 4 weeks for 16 weeks). In all patients eprosartan 600 mg once daily was used. In patients who did not reach BP control (BP < 140/90 mm Hg) after 8 weeks, hydrochlorothiazide (HCTZ) 12.5 mg daily was added. QoL was evaluated at baseline and after 16 weeks by the Psychological General Well-being Index questionnaire (PGWB).
Results After 16 weeks of treatment with eprosartan. BP was significantly decreased (154.0/99.2 vs. 129.4/85.1 mm Hg, p < 0.01), both in men and in women. At the end of the study in all patients blood pressure control was obtained. HCTZ was added to 14 patients (16.5%) during the study. Most pronounced reduction of BP was observed in patients treated with eprosartan + thiazide-like diuretic, eprosartan + calcium antagonist and eprosartan + ACE inhibitor. After 16 weeks significant improvement of QoL (PGWB 88.4 ± 9,1 vs. 101.4 ± 10,3 points, p < 0.01) was observed. The total score of the PGWB and its subscales improved significantly in both sexes, except of “self-control” subscale.
Conclusions Eprosartan provides good antihypertensive efficacy and significantly improves quality of life, irrespective of gender. Higher QoL during treatment with eprosartan is strictly related to better blood pressure control.
Abstract
Material and methods The study population consisted of 85 patients with mild to moderate essential hypertension (47 men and 38 women), age 45.1 ± 13.9 yrs. Mean SBP was 154.0 mm Hg and DBP was 99.2 mm Hg. At baseline 16 patients (18.6%) were untreated, and 70 (81.4%) were treated with monotherapy: thiazide-like diuretic (14 pts), beta-blocker (13 pts), ACE inhibitor (20 pts), calcium antagonist (18 pts), alpha-blocker (2 pts), centrally acting drug (3 pts). BP and heart rate were measured at baseline and on each control visit (every 4 weeks for 16 weeks). In all patients eprosartan 600 mg once daily was used. In patients who did not reach BP control (BP < 140/90 mm Hg) after 8 weeks, hydrochlorothiazide (HCTZ) 12.5 mg daily was added. QoL was evaluated at baseline and after 16 weeks by the Psychological General Well-being Index questionnaire (PGWB).
Results After 16 weeks of treatment with eprosartan. BP was significantly decreased (154.0/99.2 vs. 129.4/85.1 mm Hg, p < 0.01), both in men and in women. At the end of the study in all patients blood pressure control was obtained. HCTZ was added to 14 patients (16.5%) during the study. Most pronounced reduction of BP was observed in patients treated with eprosartan + thiazide-like diuretic, eprosartan + calcium antagonist and eprosartan + ACE inhibitor. After 16 weeks significant improvement of QoL (PGWB 88.4 ± 9,1 vs. 101.4 ± 10,3 points, p < 0.01) was observed. The total score of the PGWB and its subscales improved significantly in both sexes, except of “self-control” subscale.
Conclusions Eprosartan provides good antihypertensive efficacy and significantly improves quality of life, irrespective of gender. Higher QoL during treatment with eprosartan is strictly related to better blood pressure control.
Keywords
arterial hypertension; quality of life; eprosartan
Title
Eprosartan - effect on quality of life in patients with essential hypertension
Journal
Issue
Article type
Original paper
Pages
20-27
Published online
2008-01-28
Page views
587
Article views/downloads
2517
Bibliographic record
Nadciśnienie tętnicze 2008;12(1):20-27.
Keywords
arterial hypertension
quality of life
eprosartan
Authors
Marek Klocek
Kalina Kawecka-Jaszcz